There are several treatment options available for spinal muscular atrophy (SMA), a rare genetic condition characterized by progressive muscle weakness and wasting. The disease mainly affects motor ...

The mean age at diagnosis was 0·5 years (SD 0·4) for those with SMA type 1, 1·6 years (SD 0·8) for those with SMA type 2, and 2·9 years (SD 1·7) for those with SMA type 3. As of data cutoff (Nov 1, ...

The next level to watch is the 100-day Simple Moving Average (SMA) at 0.6425, followed by the weekly top at 0.6549 (November 25), and finally the 200-day SMA at 0.6553. On the downside ...

BMZ Innovation Group, a leading European manufacturer of cross-industry lithium-ion battery systems, is offering the opportunity of a battery technology-related fellowship for a participant of The ...

Evrysdi is the only non-invasive disease-modifying treatment for SMA. The 5 mg Evrysdi tablet can either be swallowed whole or dispersed in water. “Evrysdi has robust potential to modify the SMA ...